Join us in our mission

With the diagnostic and therapeutic strategies used today, about 25% of all men diagnosed with prostate cancer die from their disease due to the development of metastases. We are convinced we can improve outcome for these patients.

No therapy-predictive markers for metastatic prostate cancer exist in clinic today. Methods for complex sample analysis, creating extended logistics, increased costs, and delayed patient management are emerging on the market. Our solution based on digital pathology is presumed to be cost-effective and easy to interpret in clinical routine. Our solution for liquid biopsy analysis allows monitoring treatment response/relapse overtime.

Current status
The development of a software prototype for AI-based digital imaging analysis of tumor cell division and differentiation, and a prototype gene panel for determining metastasis subtype from analysis of circulating tumor cells have been initiated. Next, prototypes will be used for PoC studies in large retrospective patient cohorts and for future clinical trails. For each product patent applications have been filed in US and Europe (Aug 2021).

We are seeking investors and partners with interest in improving prostate cancer treatment and patient care.